



MEETING AGENDA

DIVISION	Iowa Medicaid Quality Improvement Organization (QIO)		
MEETING TITLE	Clinical Advisory Committee (CAC)		
CAC CHAIR	Bill Jagiello, DO		
FACILITATOR	Heidi Weaver		
DATE	July 19, 2024	TIME	1:00pm-4:00pm
LOCATION	Zoom Meeting https://telligen.zoom.us/meeting/register/tZlsc-Cupj8pH9PoGhUezLCkSry8sZt9jq7h		

MEETING OBJECTIVES

The purpose of the CAC is to increase the efficiency, quality, and effectiveness of the Medicaid healthcare system. The CAC provides a process for physician and other healthcare provider contributions to promote quality care, member safety, cost effectiveness and positive physician and provider relations through discussion about Medicaid benefits and healthcare services.

The CAC is charged with recommending clinically appropriate healthcare utilization management and coverage decision to the Department of Health and Human Services (HHS) for the Iowa Medicaid program.

HIPAA Reminder: As a reminder to all members of the public who are presenting during the CAC meeting: Do not provide any personal health information (PHI) regarding a member covered by Iowa Medicaid Insurance that would constitute a violation of Federal HIPAA standards.

MEETING PARTICIPANTS

Iowa Medicaid	<input type="checkbox"/> Elizabeth Matney, Medicaid Director <input type="checkbox"/> Rebecca Curtiss, HHS Deputy Director of Operations <input type="checkbox"/> Paula Motsinger, HHS Bureau Chief of LTSS <input type="checkbox"/> Jenny Erdman, HHS Quality, Innovation & Medical Policy Bureau Chief <input checked="" type="checkbox"/> Bill Jagiello, DO <input type="checkbox"/> Mark Randleman, DO <input checked="" type="checkbox"/> Else Umbreit, PharmD <input checked="" type="checkbox"/> Charissa Blinkmann
Committee Members	<input checked="" type="checkbox"/> Dr. Alexandra Hubbell-Family Practice <input checked="" type="checkbox"/> Clarice Blanchard, PA-C, Family Practice/Emergency Medicine <input type="checkbox"/> Dr. Dana Danley-Family Practice <input checked="" type="checkbox"/> Dr. Dennis Zachary-Family Practice <input checked="" type="checkbox"/> Diana Smith, ARNP-Family Practice <input type="checkbox"/> Dr. Polly Ferguson-Pediatric Rheumatology <input type="checkbox"/> Dr. Chitra Reddy-Endocrinology <input checked="" type="checkbox"/> Dr. Kathleen Lange-Family Practice <input checked="" type="checkbox"/> Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist



Managed Care Organizations	<input checked="" type="checkbox"/> Dr. Paul Mulhausen, Iowa Total Care <input type="checkbox"/> Dr. Timothy Gutshall, Molina Healthcare of Iowa <input checked="" type="checkbox"/> Dr. Neal Sherman, Wellpoint
----------------------------	--

AGENDA TOPIC

Public Comment Period

- A maximum of 5 minutes will be allotted to each public guest who has submitted a signed [CAC Speaker Disclosure form](#)
- To be respectful of the meeting time if you find your topic will exceed the maximum 5-minute allotment we welcome you to submit your detailed information to CAC@dhs.state.ia.us prior to and/or post meeting.

Announcements

- **Recognition of Service:** Dr. Kathleen Lange and Dr. Dennis Zachary
- **Welcome:** Dr. Neal Sherman, Interim Medical Director, Wellpoint
- **Appreciation:** Dr. Nivedita Krishnan, Wellpoint

Approval of April 19, 2024 Meeting Minutes

Old Business

1. Serum Iron Studies

New Business

Consent Agenda

Durable Medical Equipment (5):

1. Custom Knee Orthotics
2. Enteral Products and Supplies
3. High Frequency Chest Wall Oscillation
4. Medical Foods
5. Strollers and Wheelchairs for Safety

Lab (2):

6. Gene Expression Profiling for the Management of Breast Cancer
7. Genetic Testing for Lynch Syndrome

Surgical Procedures (4):

8. Laser Linear Accelerator Based Stereotactic Radiosurgery
9. Left Ventricular Assist Device
10. Reduction Mammoplasty-Mastopexy
11. Risk Reduction Mastectomy

Physician Administered Medications (11):

12. Adakveo (crizanzumab-tmca)
13. Darzalex and Darzalex Faspro (daratumumab; daratumumab and hyaluronidase)
14. Fyarro (sirolimus protein-bound particles)
15. Monjuvi (tafasitamab-cxix)
16. Namenda (memantine) for Autism Spectrum Disorder
17. Opdualag (nivolumab and relatlimab-rmbw)
18. Rylaze [asparaginase erwinia chrysanthemi (recombinant)-rywn]



<p>19. Sarclisa (isatuximab-irfc) 20. Tecvayli (teclistamab-cqyv) 21. Uplizna (inebilizumab-cdon) 22. Zynlonta (loncastuximab tesirine-lpyl)</p>
<p>Criteria Review <u>Radiology (1):</u> 1. Functional Fraction Reserve</p> <p><u>Physician Administered Medications - New (6):</u> 2. Columvi (glofitamab-gxbm) 3. Elrexfio (elranatamab-bcmm) 4. Epkinly (epcoritamab-bysp) 5. Talvey (talquetamab-tgvs) 6. Tezspire (tezepelumab-ekko) 7. Tzield (teplizumab-mzwv)</p> <p><u>Physician Administered Medications – Review (4):</u> 8. Fasentra (benralizumab) 9. Jemperli (dostarlimab-gxly) 10. Keytruda (pembrolizumab) 11. Tepezza (teprotumumab-trbw)</p>
<p>Upcoming Meetings</p> <ul style="list-style-type: none"> • Friday, October 18, 2024 • Friday, January 17, 2025
<p>Adjournment</p>

Additional Information
<ul style="list-style-type: none"> • Iowa Medicaid CAC contact: CAC@dhs.state.ia.us
<ul style="list-style-type: none"> • Iowa Medicaid CAC webpage: https://hhs.iowa.gov/about/advisory-groups/clinical-advisory-committee-cac
<ul style="list-style-type: none"> • Guests wanting to speak during the public comment period must complete a CAC Disclosure Form and email it to CAC@dhs.state.ia.us.

Meeting Minutes (Q3 2024)

Introduction: Heidi Weaver, Iowa Medicaid QIO, welcomed everyone to the third quarterly Iowa Medicaid Clinical Advisory Committee (CAC) Meeting for 2024, and provided an overview of the house rules.

Verbal roll call of the Committee Members proceeded. After a short delay a quorum was confirmed with five of the nine members.

Announcements: Heidi introduced Committee Chairman, Dr. Jagiello, who is the Medical Director for Iowa Medicaid QIO. She presented the Meeting Objectives and the instructions for the Public Comment period presentations, with the use of a visible timer for each Public Guest



Speaker and allotment of 5 minutes to present. She also provided the new CAC email available for any correspondence at CAC@dhs.state.ia.us.

Dr. Jagiello offered recognition of appreciation for Dr. Lange and Dr. Zachary, two committee members who have served the Clinical Advisory Committee for the past 6 years.

Dr. Lange provided remarks commemorating her 6 years of service with gratitude.

He next offered appreciation for Dr. Krishnan's service as medical director of Wellpoint, who has now accepted a new position within their parent company Elevance, and of Dr. Neal Sherman, who is an interim medical director, who will be filling her position.

Approval of the April 19, 2024 Minutes: Approved by votes below.

Dr. Jagiello opened for a vote to approve the minutes, with no requests for any changes or corrections.

First motion to approve by Dr. Lange
Second motion to approve by Dr. Sahu

Committee Member by vote:

Decision-Motion approved by 5 of 9 members present.

- Dr. Alexandra Hubbell-Family Practice
- Clarice Blanchard, PA-C, Family Practice/Emergency Medicine
- Dr. Dana Danley-Family Practice (absent)
- Dr. Dennis Zachary-Family Practice (absent)
- Diana Smith, ARNP-Family Practice
- Dr. Polly Ferguson-Pediatric Rheumatology (absent)
- Dr. Chitra Reddy-Endocrinology (absent)
- Dr. Kathleen Lange-Family Practice
- Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist

Old Business:

1. Serum Iron Studies:

Dr. presented the expanded version with new codes that have been added in red and have made it a more comprehensive list.

First motion to approve by Diana Smith
Second motion to approve by Clarice Blanchard
Committee Member by roll call vote:

Decision-Motion approved by 6 of 9 members present.

- Dr. Alexandra Hubbell-Family Practice
- Clarice Blanchard, PA-C, Family Practice/Emergency Medicine
- Dr. Dana Danley-Family Practice (absent)
- Dr. Dennis Zachary-Family Practice
- Diana Smith, ARNP-Family Practice
- Dr. Polly Ferguson-Pediatric Rheumatology (absent)
- Dr. Chitra Reddy-Endocrinology (absent)



- Dr. Kathleen Lange-Family Practice
- Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist

Heidi Weaver announced the next order of business, Consent Agenda.

Consent Agenda:

Dr. Jagiello provided the purpose of the Consent Agenda, then opened it up to the Committee Members for review. There were no requests or concerns expressed. Dr. Else Umbreit added a comment to item 12, Adakveo, which did have an update from the FDA of additional language to the dosage and administration info in June 2024 and read the changes to the group, but nothing that changes the policy at this time.

There was an opportunity for public comment, with no comments presented. Dr. Jagiello indicated that if there was a registered speaker to speak to item 21, Uplizna, who perhaps couldn't make it onto the meeting due to the nationwide technical issues, he requested that Heidi and/or Charissa communicate to them it was on the Consent Agenda and if they had information they'd like to share, it can be brought up at a future date to ensure they have that opportunity.

First motion to approve by Dr. Hubbell

Second motion to approve by Dr. Lange

Committee Member by roll call vote:

Decision-Motion approved by 6 of 9 members present.

- Dr. Alexandra Hubbell-Family Practice
- Clarice Blanchard, PA-C, Family Practice/Emergency Medicine
- Dr. Dana Danley-Family Practice (absent)
- Dr. Dennis Zachary-Family Practice
- Diana Smith, ARNP-Family Practice
- Dr. Polly Ferguson-Pediatric Rheumatology (absent)
- Dr. Chitra Reddy-Endocrinology (absent)
- Dr. Kathleen Lange-Family Practice
- Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist

Heidi announced the next order of business, Criteria Review.

Criteria Review:

1. Functional Fraction Reserve (RAD-005)

Dr. Jagiello presented the medical criteria and review of the contraindications, coding, compliance and the recommendations. He opened for Committee Member comments, with no comments, and no further public comment, he motioned for approval from the Committee.

First motion to approve by Dr. Zachary

Second motion to approve by Dr. Sahu

Committee Member by roll call vote:

Decision-Motion approved by 6 of 9 members present.

- Dr. Alexandra Hubbell-Family Practice
- Clarice Blanchard, PA-C, Family Practice/Emergency Medicine
- Dr. Dana Danley-Family Practice (absent)



- Dr. Dennis Zachary-Family Practice
- Diana Smith, ARNP-Family Practice
- Dr. Polly Ferguson-Pediatric Rheumatology (absent)
- Dr. Chitra Reddy-Endocrinology (absent)
- Dr. Kathleen Lange-Family Practice
- Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist

2.Columvi (glofitamab-gxhm) (PAM-070)

Dr. Umbreit presented the medical criteria for this new policy. She provided the overview, accelerated approval status, dosing and administration and the box warning of cytokine release syndrome. She provided the criteria for prior authorization, approval duration and quantity limits with view of coding and product information. Dr. Jagiello opened to the Committee for comments, there were none. There were no public presenter comments.

First motion to approve by Clarice Blanchard

Second motion to approve by Dr. Zachary

Committee Member by roll call vote:

Decision-Motion approved by 6 of 9 members present.

- Dr. Alexandra Hubbell-Family Practice
- Clarice Blanchard, PA-C, Family Practice/Emergency Medicine
- Dr. Dana Danley-Family Practice (absent)
- Dr. Dennis Zachary-Family Practice
- Diana Smith, ARNP-Family Practice
- Dr. Polly Ferguson-Pediatric Rheumatology (absent)
- Dr. Chitra Reddy-Endocrinology (absent)
- Dr. Kathleen Lange-Family Practice
- Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist

3.Elrexfio (elranatamab-bcmm) (PAM-077)

Dr. Umbreit presented the medical criteria for this new policy. She provided the overview, accelerated approval status, dosing and administration and the box warning of cytokine release syndrome and neurologic toxicity including immune effector cell-associated neurotoxicity syndrome. She provided the criteria for prior authorization, approval duration and quantity limits with view of coding and product information. Dr. Jagiello asked for clarification about the strike over hcpcs code, Dr. Umbreit indicated the initial code was a temporary “c” code, and since the effective date of the codes are included, she indicated it by date, then permanent code was added as effective at a later date. Dr. Jagiello opened to the Committee for comments, there were none. There were no public presenter comments.

First motion to approve Dr. Zachary

Second motion to approve by Dr. Hubbell

Committee Member by roll call vote:

Decision-Motion approved by 6 of 9 members present.

- Dr. Alexandra Hubbell-Family Practice
- Clarice Blanchard, PA-C, Family Practice/Emergency Medicine

- Dr. Dana Danley-Family Practice (absent)
- Dr. Dennis Zachary-Family Practice
- Diana Smith, ARNP-Family Practice
- Dr. Polly Ferguson-Pediatric Rheumatology (absent)
- Dr. Chitra Reddy-Endocrinology (absent)
- Dr. Kathleen Lange-Family Practice
- Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist

4. Epcoritamab-bysp (PAM-078)

Dr. Umbreit presented the medical criteria for this new policy. She prefaced it with the process timeline taken for the committee review and policy review, which happened early June, and then on June 26th, there was an additional indication approved for follicular relapse or refractory follicular lymphoma that was not addressed, but will be added with the next review and if a request comes in, the reviewer can reference current prescribing information or NCCN for any FDA indications that aren't included in the policy. She provided the overview, accelerated approval status, with the new indication also under accelerated approval. She provided dosing and administration, with overview of the warning for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). She provided the criteria for prior authorization, approval duration and quantity limits and coding and product information viewing. It was also initially assigned a temporary code which was included. Dr. Jagiello opened to the Committee for comments, there were none. There were no public presenter comments.

First motion to approve Dr. Lange

Second motion to approve by Dr. Zachary

Committee Member by roll call vote:

Decision-Motion approved by 6 of 9 members present.

- Dr. Alexandra Hubbell-Family Practice
- Clarice Blanchard, PA-C, Family Practice/Emergency Medicine
- Dr. Dana Danley-Family Practice (absent)
- Dr. Dennis Zachary-Family Practice
- Diana Smith, ARNP-Family Practice
- Dr. Polly Ferguson-Pediatric Rheumatology (absent)
- Dr. Chitra Reddy-Endocrinology (absent)
- Dr. Kathleen Lange-Family Practice
- Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist

5. Talquetamab-tgvs (PAM-079)

Dr. Umbreit presented the medical criteria for this new policy. Indication was approved under accelerated approval. She provided the dosing schedule and administration with step up dosing and does carry the warning for risk of warning for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), so patients need to be hospitalized for 48 hrs after administration of all doses within the step-up dosing schedule. She provided the criteria for prior authorization, approval duration and quantity limits and coding and product information viewing. Dr. Jagiello opened to the Committee for comments, there were none. There were no public presenter comments.



First motion to approve Dr. Zachary
Second motion to approve by Diana Smith
Committee Member by roll call vote:

Decision-Motion approved by 6 of 9 members present.

- Dr. Alexandra Hubbell-Family Practice
- Clarice Blanchard, PA-C, Family Practice/Emergency Medicine
- Dr. Dana Danley-Family Practice (**absent**)
- Dr. Dennis Zachary-Family Practice
- Diana Smith, ARNP-Family Practice
- Dr. Polly Ferguson-Pediatric Rheumatology (**absent**)
- Dr. Chitra Reddy-Endocrinology (**absent**)
- Dr. Kathleen Lange-Family Practice
- Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist

6. Tezspire (tezepelumab-ekko) (PAM-080)

Dr. Jagiello acknowledged a public speaker in attendance and indicated the opportunity for comments after the presentation of the policy. Dr. Umbreit presented the medical criteria for this new policy. She provided the overview, accelerated approval status, dosing and administration and criteria for prior authorization, with approval duration and quantity limits and coding and product information viewing. Dr. Jagiello opened for Public Comments.

Public Comment: Dr. Claire Elson, PharmD, educator with Amgen Medical Affairs, provided comments and welcomed questions.

Dr. Jagiello opened to the Committee for comments, there were none.

First motion to approve Dr. Zachary
Second motion to approve by Clarice Blanchard
Committee Member by roll call vote:

Decision-Motion approved by 6 of 9 members present.

- Dr. Alexandra Hubbell-Family Practice
- Clarice Blanchard, PA-C, Family Practice/Emergency Medicine
- Dr. Dana Danley-Family Practice (**absent**)
- Dr. Dennis Zachary-Family Practice
- Diana Smith, ARNP-Family Practice (voted by chat)
- Dr. Polly Ferguson-Pediatric Rheumatology (**absent**)
- Dr. Chitra Reddy-Endocrinology (**absent**)
- Dr. Kathleen Lange-Family Practice
- Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist

7. Tzield (teplizumab-mzwv) (PAM-082)

Dr. Umbreit presented the medical criteria for this new policy. She provided the criteria overview with dosage and administration with benefit category and descriptive narrative. Then she presented the guidelines and criteria for prior authorization, approval duration and quantity limits with view of coding and product information and compliance. Dr. Jagiello opened to the Committee for comments, there were none. There were no public presenter comments.



First motion to approve Dr. Lange

Second motion to approve by Dr. Zachary

Committee Member by roll call vote:

Decision-Motion approved by 6 of 9 members present.

- Dr. Alexandra Hubbell-Family Practice
- Clarice Blanchard, PA-C, Family Practice/Emergency Medicine
- Dr. Dana Danley-Family Practice (absent)
- Dr. Dennis Zachary-Family Practice
- Diana Smith, ARNP-Family Practice (voted by chat)
- Dr. Polly Ferguson-Pediatric Rheumatology (absent)
- Dr. Chitra Reddy-Endocrinology (absent)
- Dr. Kathleen Lange-Family Practice
- Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist

8.Fasenra (benralizumab) (PAM-032)

Dr. Umbreit presented the medical criteria for the existing policy. She updated the overview table, as the indication on April 5, 2024, the FDA approved for use in ages 6 years of age and older for eosinophilic type. She adjusted the new age requirements and dosage and administration. She updated the abbreviations section. She reviewed the criteria for prior authorization with the changes to criteria 4, from previously 12 years of age, to now 6 years of age or older, and criteria 9, she added the dosing into the policy criteria for age and weight, for continuation she added the addition of the dosing information into criteria 6. She provided the approval duration and quantity limits with the view of coding and product information. Dr. Jagiello opened for public comments.

Public comment: Dr. Sunny Hirpara, PharmD, from medical affairs for AstraZeneca, provided comments in support of the criteria as written for appropriate access, and their new criteria as well as clarified no intention to bring the auto-injector to market at this time for the 10 mg.

Dr. Jagiello opened to the Committee for comments, there were none.

First motion to approve Dr. Zachary

Second motion to approve by Dr. Sahu

Committee Member by roll call vote:

Decision-Motion approved by 6 of 9 members present.

- Dr. Alexandra Hubbell-Family Practice
- Clarice Blanchard, PA-C, Family Practice/Emergency Medicine
- Dr. Dana Danley-Family Practice (absent)
- Dr. Dennis Zachary-Family Practice
- Diana Smith, ARNP-Family Practice (voted by chat)
- Dr. Polly Ferguson-Pediatric Rheumatology (absent)
- Dr. Chitra Reddy-Endocrinology (absent)
- Dr. Kathleen Lange-Family Practice
- Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist

9.Jemperli (dostarlimab-gxly) (PAM-046)



Dr. Umbreit presented the medical criteria for the existing policy. She added the new indication approved 07/31/2023, just after the July meeting last year, and updated the overview table to include (B) and provided recommended dosage. She reviewed the NCCN guidelines and prior authorization criteria with the difference added of (B.), 2-4 are the same and criteria 5 as changed for the new indication. She reviewed the solid tumor, mismatch repair deficient information with no changes, but she added the dosing information again and the types of advanced solid tumors to give more clarity to that and continuation criteria with the only change was number 4 (a)(b). She reviewed the approval duration and quantity limits overview (correction to subsequent authorization, quantity limits from 12 months to 1,000 mg every 6 weeks). Dr. Jagiello opened to the Committee for comments, there were none. There were no public presenter comments.

First motion to approve Dr. Zachary

Second motion to approve by Dr. Lange

Committee Member by roll call vote:

Decision-Motion approved by 6 of 9 members present.

- Dr. Alexandra Hubbell-Family Practice
- Clarice Blanchard, PA-C, Family Practice/Emergency Medicine
- Dr. Dana Danley-Family Practice (absent)
- Dr. Dennis Zachary-Family Practice
- Diana Smith, ARNP-Family Practice (voted by chat)
- Dr. Polly Ferguson-Pediatric Rheumatology (absent)
- Dr. Chitra Reddy-Endocrinology (absent)
- Dr. Kathleen Lange-Family Practice
- Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist

10.Keytruda (pembrolizumab) (PAM-008)

Dr. Umbreit presented the medical criteria for the existing policy. A new indication was received (June 17) after the annual review had been completed. The clinical reviewer can reference current prescribing information for any FDA indications that aren't included in the policy. She advised it's a long policy and indicated she'd go through the changes and has also updated the NCCN guidelines and references. Non-small cell lung cancer (NSCLC) (FDA-approved-10/16/23) letter (f.) was added. Urothelial Carcinoma modified indication and converted from accelerated approval to regular approval (FDA approved 12/15/2023). Gastric Cancer an indication was modified (FDA approved 11/16/2023) and new indication (FDA approved 11/17/2023) letter (b.). Cervical Cancer received a new indication (FDA approved 01/12/2024) letter (b.). Hepatocellular Carcinoma modified indication and converted to regular approval (FDA approved 01/25/2024). Biliary Tract Cancer had a new indication (FDA approved 10/31/23) (a.). Merkel Cell Carcinoma was converted from accelerated to regular approval (FDA approved 10/12/23). She updated all of the new FDA dosing for the indications she included in the Appendix, and the coding section with the ICD10 codes for those indications. She further reviewed Non-small cell lung cancer letter (e.). Classical Hodgkin Lymphoma she added the Lansky Play scale and Karnofsky Performance Status to the criteria per age, where they have a pediatric approval. Primary Mediastinal Large B-Cell Lymphoma (PMBCL) she added the performance status scores. Urothelial Carcinoma updated to match the new FDA indication, previously indicated for members who are not eligible for cisplatin contained chemotherapy, was removed from the FDA approved indication so she removed it from the criteria. Microsatellite

Instability-High (MSI-H) or Mismatch Repair Deficient Cancer (dMMR), she had added the performance status scores. Gastric Cancer adding the new indication for 5. (b.). Esophageal Cancer number 3. was split into two criteria instead of remaining just one. Cervical Cancer criteria 5 (a.) is the new criteria indication approved. Hepatocellular Carcinoma the indication language changed, so she updated to match the language. Biliary Tract Cancer was a new indication and updated. Merkel Cell Carcinoma the performance status scores were added. Renal Cell Carcinoma the performance status score was added. Endometrial Carcinoma had a new indication added 7.(a.). Tumor Mutational Burden-High Cancer the performance status scores were added. Triple-Negative Breast Cancer the performance status scores were added. The new indications added with the newest approved indication from June 17th, which will be added into the next review period. She provided the approval duration and quantity limits, and not to exceed FDA approved dosing, see Appendix A. Dr. Jagiello opened to the Committee for comments, there were none. There were no public presenter comments.

First motion to approve Dr. Zachary

Second motion to approve by Dr. Sahu

Committee Member by roll call vote:

Decision-Motion approved by 6 of 9 members present.

- Dr. Alexandra Hubbell-Family Practice
- Clarice Blanchard, PA-C, Family Practice/Emergency Medicine
- Dr. Dana Danley-Family Practice (absent)
- Dr. Dennis Zachary-Family Practice
- Diana Smith, ARNP-Family Practice (voted by chat)
- Dr. Polly Ferguson-Pediatric Rheumatology (absent)
- Dr. Chitra Reddy-Endocrinology (absent)
- Dr. Kathleen Lange-Family Practice
- Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist

11.Tepezza (teprotumumab-trbw) (PAM-022)

Dr. Umbreit presented the medical criteria for the existing policy. There was a change to the limitation for the clinical activity score on whether or not a person would be eligible, and now the new FDA approved indication is now for treatment of thyroid eye disease regardless of activity or duration. She provided the overview, dosage and administration and removed the criteria for the requirement of the clinical activity score. She provided the criteria for prior authorization, the information for approval duration and quantity limits. Else requested review by the Committee to of the approval duration for the quantity for additional time to ensure the 8 doses can be received. Dr. Lange and Dr. Sahu advised it would be acceptable. Update to the policy Approval Duration from 6 months to 9 months, limited to 8 total infusions. Dr. Lange and Dr. Sahu agreed it would be sufficient. Dr. Jagiello opened for public presentation.

Public comment: Dr. Linda Morgan, Regional Medical Director, Amgen, provided comment that the approval duration change from 6 to 9 months will be a great benefit for the patients and was appreciative of the consideration.

First motion to approve Dr. Lange

Second motion to approve by Dr. Zachary

Committee Member by roll call vote:



Decision-Motion approved by 6 of 9 members present.

- Dr. Alexandra Hubbell-Family Practice
- Clarice Blanchard, PA-C, Family Practice/Emergency Medicine
- Dr. Dana Danley-Family Practice (**absent**)
- Dr. Dennis Zachary-Family Practice
- Diana Smith, ARNP-Family Practice
- Dr. Polly Ferguson-Pediatric Rheumatology (**absent**)
- Dr. Chitra Reddy-Endocrinology (**absent**)
- Dr. Kathleen Lange-Family Practice
- Dr. Geetanjali Sahu-Child and Adolescent Psychiatrist

Dr. Zachary provided closing remarks commemorating his 6 years of service on the committee and spoke to the great work being done.

Heidi Weaver announced the upcoming meetings and thanked all Committee Members.

Upcoming Meetings:

Friday, October 18, 2024

Friday, January 17, 2025

Dr. Jagiello announced appreciation of everyone in attendance today, given the CrowdStrike outage, affecting folks across the country.

Motion for Adjournment:

First motion by Dr. Lange, Second motion by Dr. Zachary. All approved.

Dr. Jagiello adjourned the meeting.